MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression

Journal of Clinical Investigation

Volumn 126, Issue 12, 2016, Pages 4585-4602

  Dallavalle, Cecilia ^a   Albino, Domenico ^a   Civenni, Gianluca ^a   Merulla, Jessica ^a   Ostano, Paola ^b   Mello Grand, Maurizia ^b   Rossi, Simona ^a   Losa, Marco ^a   D'Ambrosio, Gioacchino ^c   Sessa, Fausto ^d   Thalmann, George N ^e   Garcia Escudero, Ramon ^a,f   Zitella, Andrea ^g   Chiorino, Giovanna ^b   Catapano, Carlo V ^a,h,i   Carbone, Giuseppina M ^a,h  

^a INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^b Laboratory of Cancer Genomics   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e UNIVERSITY OF BERN   (Switzerland)

^f CIEMAT   (Spain)

^g UNIVERSITY OF TURIN   (Italy)

^h ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

ⁱ UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 424; STAT3 PROTEIN; UBIQUITIN PROTEIN LIGASE COP1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; EHF PROTEIN, HUMAN; MIRN424 MICRORNA, HUMAN; RFWD2 PROTEIN, HUMAN; RNA; TRANSCRIPTION FACTOR; TUMOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CANCER CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; COMPARATIVE STUDY; DISEASE ASSOCIATION; DU145 CELL LINE; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE EPITHELIUM CELL; PROSTATE TUMOR; PROTEIN DEGRADATION; PROTEIN METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE EXPRESSION; TRANSIENT EXPRESSION; TUMOR GROWTH; UBIQUITINATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CANCER STEM CELL; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RNA, NEOPLASM; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 85003036888     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86505     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349(4):366-381.
3. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24(18):1967-2000.
4. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755-768.
5. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8(7):497-511.
6. Tomlins SA, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-648.
7. Tomlins SA, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39(1):41-51.
8. Albino D, et al. ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. Cancer Res. 2012;72(11):2889-2900.
9. Cangemi R, et al. Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer. Oncogene. 2008;27(20):2877-2885.
10. Kunderfranco P, et al. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One. 2010;5(5):e10547.
11. Longoni N, et al. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression. Cancer Res. 2013;73(14):4533-4547.
12. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.
13. Croce CM. Causes and consequences of micro-RNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-714.
14. Catto JW, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59(5):671-681.
15. Fang YX, Gao WQ. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. 2014;33(2):135-147.
16. Migliorini D, et al. Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J Clin Invest. 2011;121(4):1329-1343.
17. Micel LN, Tentler JJ, Smith PG, Eckhardt GS. Role of ubiquitin ligases and the proteasome in onco-genesis: novel targets for anticancer therapies. J Clin Oncol. 2013;31(9):1231-1238.
18. Theurillat JP, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346(6205):85-89.
19. Vitari AC, et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature. 2011;474(7351):403-406.
20. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
21. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736-746.
22. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011-1025.
23. Civenni G, et al. RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer Res. 2013;73(22):6816-6827.
24. Mora LB, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62(22):6659-6666.
25. Schroeder A, et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 2014;74(4):1227-1237.
26. Kroon P, et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 2013;73(16):5288-5298.
27. Baffert F, et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther. 2010;9(7):1945-1955.
28. Finnerty JR, Wang WX, Hébert SS, Wilfred BR, Mao G, Nelson PT. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol. 2010;402(3):491-509.
29. Banyard J, et al. Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep. 2013;3:3151.
30. Zhou W, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25(4):501-515.
31. Qin HR, et al. Activation of signal transducer and activator of transcription 3 through a phosphomi-metic serine 727 promotes prostate tumorigene-sis independent of tyrosine 705 phosphorylation. Cancer Res. 2008;68(19):7736-7741.
32. Sellier H, Rébillard A, Guette C, Barré B, Coqueret O. How should we define STAT3 as an oncogene and as a potential target for therapy? JAKSTAT. 2013;2(3):e24716.
33. Cheng CJ, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenviron-ment. Nature. 2015;518(7537):107-110.
34. Soifer HS, Rossi JJ, Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther. 2007;15(12):2070-2079.
35. Rahimian A, et al. Bypassing the maturation arrest in myeloid cell line U937 by over-expression of microRNA-424. Hematology. 2011;16(5):298-302.
36. Krüger J, Rehmsmeier M. RNAhybrid: micro-RNA target prediction easy, fast and flexible. Nucleic Acids Res. 2006;34(Web Server issue):W451-W454.
37. Longoni N, et al. Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression. Oncogene. 2013;32(18):2315-2324.e1.
38. Pradervand S, et al. Impact of normalization on miRNA microarray expression profiling. RNA. 2009;15(3):493-501.
39. Prtilo A, et al. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J Urol. 2005;174(5):1814-1818.